Ogu UO - Search Results

1

Hydroxyurea at escalated dose versus fixed low-dose hydroxyurea in adults with sickle cell disease.

Ogu UO, Mukhopadhyay A, Patel K, Nelson MN, Strahan KS, Wu L, Smeltzer MP, Ataga KI. Ogu UO, et al. Eur J Haematol. 2024 Mar;112(3):466-474. doi: 10.1111/ejh.14138. Epub 2023 Nov 29. Eur J Haematol. 2024. PMID: 38019026 Review.

2

Urinary angiotensinogen is associated with albuminuria in adults with sickle cell anaemia.

Elsherif L, Kanthakumar P, Afolabi J, Stratton AF, Ogu U, Nelson M, Mukhopadhyay A, Smeltzer MP, Adebiyi A, Ataga KI. Elsherif L, et al. Br J Haematol. 2023 Aug;202(3):669-673. doi: 10.1111/bjh.18862. Epub 2023 May 15. Br J Haematol. 2023. PMID: 37189288

3

Hydroxyurea and fetal hemoglobin effect on leg ulcers in patients with sickle cell disease.

Tolu SS, Crouch A, Choi J, Gao Q, Reyes-Gil M, Ogu UO, Vinces G, Minniti CP. Tolu SS, et al. Among authors: ogu uo. Ann Hematol. 2022 Mar;101(3):541-548. doi: 10.1007/s00277-021-04635-4. Epub 2022 Jan 18. Ann Hematol. 2022. PMID: 35039901

4

Sickle cell disease in the new era: advances in drug treatment.

Lee MT, Ogu UO. Lee MT, et al. Among authors: ogu uo. Transfus Apher Sci. 2022 Oct;61(5):103555. doi: 10.1016/j.transci.2022.103555. Epub 2022 Aug 29. Transfus Apher Sci. 2022. PMID: 36096995 Review.

5

Management of Sickle Cell Disease Complications Beyond Acute Chest Syndrome.

Ogu UO, Badamosi NU, Camacho PE, Freire AX, Adams-Graves P. Ogu UO, et al. J Blood Med. 2021 Feb 25;12:101-114. doi: 10.2147/JBM.S291394. eCollection 2021. J Blood Med. 2021. PMID: 33658881 Free PMC article. Review.

6

Patient-focused inquiry on hydroxyurea therapy adherence and reasons for discontinuation in adults with sickle cell disease.

Bradford C, Miodownik H, Thomas M, Ogu UO, Minniti CP. Bradford C, et al. Among authors: ogu uo. Am J Hematol. 2022 Mar 1;97(3):E93-E95. doi: 10.1002/ajh.26438. Epub 2021 Dec 22. Am J Hematol. 2022. PMID: 34914130 Free article. No abstract available.

7

Treatment of less-common complications of sickle cell disease.

Ogu UO. Ogu UO. Clin Adv Hematol Oncol. 2023 Nov;21(11):600-602. Clin Adv Hematol Oncol. 2023. PMID: 37948597 No abstract available.

8

L-glutamine use in adults with sickle cell disease: Clinical trials where success meets reality.

Ogu UO, Thomas M, Chan F, Vattappally L, Sebastian G, Crouch A, You S, Minniti CP. Ogu UO, et al. Am J Hematol. 2021 Jan;96(1):E38-E40. doi: 10.1002/ajh.26021. Epub 2020 Oct 29. Am J Hematol. 2021. PMID: 33068033 Free article. No abstract available.

9

MicroRNA29B induces fetal hemoglobin via inhibition of the HBG repressor protein MYB in vitro and in humanized sickle cell mice.

Gu Q, Palani CD, Smith A, Li B, Amos-Abanyie EK, Ogu U, Lu L, Pace BS, Starlard-Davenport A. Gu Q, et al. Front Med (Lausanne). 2022 Nov 25;9:1043686. doi: 10.3389/fmed.2022.1043686. eCollection 2022. Front Med (Lausanne). 2022. PMID: 36507536 Free PMC article.

10

First Report of Compound Heterozygosity for Hb S (HBB: c.20A>T) and Hb Haringey (HBB: c.131A>G).

Ogu UO, Reyes Gil M, Tolu SS, Acharya SA, Minniti CP. Ogu UO, et al. Hemoglobin. 2021 Mar;45(2):136-139. doi: 10.1080/03630269.2021.1926276. Epub 2021 Jun 16. Hemoglobin. 2021. PMID: 34134586

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

16 results

Search Page

Filters